News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Taglich Brothers Initiates Coverage on ALR Technologies Inc.


4/5/2012 9:02:23 AM

NEW YORK, NY--(Marketwire - April 05, 2012) -

Taglich Brothers, Inc. announces it initiated coverage of ALR Technologies Inc. (OTCBB: ALRT).

ALR Technologies Inc., headquartered in Richmond, Virginia, was established in 1987. ALRT is commercializing Health-e-Connect (HeC), an Internet-based compliance monitoring system (IBGMS) cleared by the FDA in October 2011. The HeC software package, compliant with HIPAA and compatible with electronic medical records systems, supports patients' compliance with their treatment regimens and enables clinicians to remotely monitor and communicate with patients when they are not compliant.

ALR has targeted the US diabetes care market due to its size, the growing prevalence of the disease, its cost burden on the healthcare system, lax patient compliance and waste in the form of health insurers' overpayments for diabetic supplies. Large-scale commercialization of HeC will be facilitated by electronically registered blood glucose self-monitoring data, which is significantly more accurate than paper logs that are often indifferently maintained by patients.

Alert Technologies is formulating a multi-pronged marketing strategy that aims to offer HeC-based data and services to three end markets: pharmaceutical manufacturers, retail drug store chains, and health insurers. As acceptance of the system widens, revenue growth momentum should accelerate, enabling ALR to establish an initial presence in all three markets within two years after HeC is commercialized.

The complete 19-page report is available at www.taglichbrothers.com.

We do not undertake to advise you as to changes in figures or our views. This is not a solicitation of any order to buy or sell. Taglich Brothers, Inc. is fully disclosed with its clearing firm, Pershing, LLC, is not a market maker and does not sell to or buy from customers on a principal basis. The above statement is the opinion of Taglich Brothers, Inc. and is not a guarantee that the target price for the stock will be met or that predicted business results for the company will occur. There may be instances when fundamental, technical and quantitative opinions contained in this report are not in concert. We, our affiliates, any officer, director or stockholder or any member of their families may from time to time purchase or sell any of the above-mentioned or related securities. Analysts and members of the Research Department are prohibited from buying or selling securities issued by the companies that Taglich Brothers, Inc. has a research relationship with, except if ownership of such securities was prior to the start of such relationship, then an Analyst or member of the Research Department may sell such securities after obtaining expressed written permission from Compliance. As of the date of this report no Taglich Brothers, Inc. employees had a position in the stock of the company mentioned in this report.

All research issued by Taglich Brothers, Inc. is based on public information. In November 2011 the company paid an initial monetary engagement fee of US$4,500 to Taglich Brothers, Inc. representing payment for the first three months of creation and dissemination of research reports, after which the company will pay Taglich Brothers, Inc. a monetary fee of US$1,500 per month for a minimum of three more months of such services.

For further information and Taglich Brothers, Inc. ownership data please refer to each individual report.


Contact:
Richard Oh
Taglich Brothers, Inc.
631-757-1500


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES